Cite

HARVARD Citation

    Hamilton, G. et al. (2019). An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer. Expert opinion on pharmacotherapy. pp. 1551-1561. [Online]. 
  
Back to record